RRC ID 35682
著者 Ishikawa R, Amano Y, Kawakami M, Sunohara M, Watanabe K, Kage H, Ohishi N, Yatomi Y, Nakajima J, Fukayama M, Nagase T, Takai D.
タイトル The chimeric transcript RUNX1-GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer.
ジャーナル Jpn J Clin Oncol
Abstract Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1-GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimera was detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although there was no significant difference in the overall survival rate between RUNX1-GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1-GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1-GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.
巻・号 46(2)
ページ 185-9
公開日 2016-2-1
DOI 10.1093/jjco/hyv187
PII hyv187
PMID 26685324
PMC PMC4731000
MeSH Aged Biomarkers, Tumor / analysis* Carcinoma, Non-Small-Cell Lung / chemistry* Carcinoma, Non-Small-Cell Lung / pathology* Chimera Core Binding Factor Alpha 2 Subunit / analysis* Female Glutaredoxins / analysis* Humans Lung Neoplasms / chemistry* Lung Neoplasms / pathology* Male Middle Aged Neoplasm Recurrence, Local Neoplasm Staging Postoperative Period Predictive Value of Tests Prognosis Survival Analysis
IF 1.914
引用数 0
WOS 分野 ONCOLOGY
リソース情報
遺伝子材料 CSII-CMV-MCS-IRES2-Bsd (RDB04385)